drug
fruquintinib
Marketedupdated 5mo agoby Takeda Pharmaceuticals USA Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(1)
Trials studying fruquintinib
- phase2A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
- phase2A Phase Ib/II Clinical Study of LBL-024 Combination Therapy in Patients With Metastatic Colorectal Carcinoma
- phase3A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan
- phase2A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer
- phase3Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
- phase2Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer
- phase2A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
- phase2SHR-3821 in Advanced Colorectal Cancer: an Exploratory Study
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 9, 2028
~1.6 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- Sep 7, 2035compositionUS 10519142
- Sep 7, 2035compositionUS 10519142
- Sep 7, 2035method-of-use (U-3753)US 11046674
- Sep 7, 2035method-of-use (U-3753)US 11046674
- Mar 23, 2032compositionUS 7829574
- Mar 23, 2032compositionUS 7829574
- May 9, 2028method-of-use (U-3753)US 82120331.6y
- May 9, 2028method-of-use (U-3753)US 82120331.6y
FDA exclusivities (2)
- Nov 8, 2028NCENew Chemical Entity (5y)2.1y
- Nov 8, 2028NCENew Chemical Entity (5y)2.1y
News(1)
- FDA delays approval decision for Exelixis' tyrosine kinase inhibitor in colorectal cancerThe FDA has delayed its approval decision for Exelixis’ oral kinase inhibitor in combination with Roche’s Tecentriq for the treatment of metastatic colorectal cancer.fiercebiotech · 28d ago
Data sources
last refreshed 36m ago
Found something off?
comments(0)
5-min edit window · permanent after that